A relevant aspect of the cutaneous alterations provoked by EGFR inhibitors is the chance that they can require an interruption in anti-tumor treatment; however, there is a complete accord that suspension of anti-EGFR treatment-based therapy should be avoided [147]. Here, EGFR is linked to neoplasm.